PMID- 25685786
OWN - NLM
STAT- MEDLINE
DCOM- 20151110
LR  - 20220331
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2015
DP  - 2015
TI  - mTOR kinase: a possible pharmacological target in the management of chronic pain.
PG  - 394257
LID - 10.1155/2015/394257 [doi]
LID - 394257
AB  - Chronic pain represents a major public health problem worldwide. Current 
      pharmacological treatments for chronic pain syndromes, including neuropathic 
      pain, are only partially effective, with significant pain relief achieved in 
      40-60% of patients. Recent studies suggest that the mammalian target of rapamycin 
      (mTOR) kinase and downstream effectors may be implicated in the development of 
      chronic inflammatory, neuropathic, and cancer pain. The expression and activity 
      of mTOR have been detected in peripheral and central regions involved in pain 
      transmission. mTOR immunoreactivity was found in primary sensory axons, in dorsal 
      root ganglia (DRG), and in dorsal horn neurons. This kinase is a master regulator 
      of protein synthesis, and it is critically involved in the regulation of several 
      neuronal functions, including the synaptic plasticity that is a major mechanism 
      leading to the development of chronic pain. Enhanced activation of this pathway 
      is present in different experimental models of chronic pain. Consistently, 
      pharmacological inhibition of the kinase activity turned out to have significant 
      antinociceptive effects in several experimental models of inflammatory and 
      neuropathic pain. We will review the main evidence from animal and human studies 
      supporting the hypothesis that mTOR may be a novel pharmacological target for the 
      management of chronic pain.
FAU - Lisi, Lucia
AU  - Lisi L
AUID- ORCID: 0000-0003-1397-2426
AD  - Institute of Pharmacology, Catholic University Medical School, Largo F. Vito 1, 
      00168 Rome, Italy.
FAU - Aceto, Paola
AU  - Aceto P
AD  - Department of Anesthesiology and Intensive Care, A. Gemelli Hospital, Catholic 
      University Medical School, 00168 Rome, Italy.
FAU - Navarra, Pierluigi
AU  - Navarra P
AD  - Institute of Pharmacology, Catholic University Medical School, Largo F. Vito 1, 
      00168 Rome, Italy.
FAU - Dello Russo, Cinzia
AU  - Dello Russo C
AUID- ORCID: 0000-0002-2538-3832
AD  - Institute of Pharmacology, Catholic University Medical School, Largo F. Vito 1, 
      00168 Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150101
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - *Chronic Pain/drug therapy/enzymology
MH  - Ganglia, Spinal/*enzymology
MH  - Humans
MH  - *Neuralgia/drug therapy/enzymology
MH  - *Pain Management
MH  - Sensory Receptor Cells/*enzymology
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/*metabolism
PMC - PMC4313067
EDAT- 2015/02/17 06:00
MHDA- 2015/11/11 06:00
PMCR- 2015/01/01
CRDT- 2015/02/17 06:00
PHST- 2014/05/16 00:00 [received]
PHST- 2014/09/12 00:00 [accepted]
PHST- 2015/02/17 06:00 [entrez]
PHST- 2015/02/17 06:00 [pubmed]
PHST- 2015/11/11 06:00 [medline]
PHST- 2015/01/01 00:00 [pmc-release]
AID - 10.1155/2015/394257 [doi]
PST - ppublish
SO  - Biomed Res Int. 2015;2015:394257. doi: 10.1155/2015/394257. Epub 2015 Jan 1.